Status:
ACTIVE_NOT_RECRUITING
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Pancreatic Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
Eligibility Criteria
Inclusion
- Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
- Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type for which the patient was eligible and willing to receive.
- Adequate bone marrow, kidney and liver function
- Performance status of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion
- • Prior treatment targeting LAIR1
Key Trial Info
Start Date :
May 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT05311618
Start Date
May 11 2022
End Date
June 1 2025
Last Update
April 1 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
SCRI Denver
Denver, Colorado, United States, 80218
2
Yale Cancer Center
New Haven, Connecticut, United States, 06520
3
Henry Ford Health System
Detroit, Michigan, United States, 48202
4
START Midwest
Grand Rapids, Michigan, United States, 49546